Immunome (NASDAQ:IMNM) Announces Quarterly Earnings Results

Immunome (NASDAQ:IMNM) posted its earnings results on Wednesday. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.16), Zacks reports. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%.

Immunome Trading Up 2.5 %

Shares of IMNM stock traded up $0.21 on Wednesday, hitting $8.57. The stock had a trading volume of 522,479 shares, compared to its average volume of 810,302. The firm has a market cap of $683.69 million, a P/E ratio of -1.06 and a beta of 1.93. Immunome has a twelve month low of $8.34 and a twelve month high of $26.70. The company has a fifty day moving average price of $9.89 and a two-hundred day moving average price of $11.66.

Insider Buying and Selling

In related news, CEO Clay B. Siegall bought 150,000 shares of Immunome stock in a transaction that occurred on Friday, January 31st. The stock was purchased at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the purchase, the chief executive officer now owns 669,636 shares in the company, valued at approximately $5,189,679. This trade represents a 28.87 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 8.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on IMNM. Wedbush restated an “outperform” rating and set a $33.00 price target on shares of Immunome in a research note on Monday, March 10th. Lifesci Capital started coverage on shares of Immunome in a report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 target price for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Immunome presently has an average rating of “Buy” and an average target price of $27.17.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.